spacer
home > ebr > spring 2002 > preclinical and clinical evaluation of therapeutic vaccines - 21st-22nd january 2002, london
PUBLICATIONS
European Biopharmaceutical Review

Preclinical and Clinical Evaluation of Therapeutic Vaccines - 21st-22nd January 2002, London

Since as long ago as the 1890s, when William Coley used streptococcal cultures to treat patients with advanced sarcoma, it has been known that the immune system can be prompted to attack cancer cells. More recently, melanoma tumours in animals have been shown to regress when injected with modified autologous cancer cells primed to stimulate an immune response. And now, somewhat like the resurgence of interest surrounding recent therapeutic success with monoclonal antibodies, the concept of stimulating the immune system to recognise and destroy foreign or indeed tumour cells, so-called 'therapeutic vaccines', is, it seems, again in vogue.This kind of technology is distinct from normal vaccination in that the patient already has the disease or condition before the vaccine is given. For any number of reasons, the patient has not already responded to the disease-associated antigens - possibly because they are 'self'-antigens (on endogenous cells such as tumour cells), or they are hidden from the immune response by directly disrupting or affecting immune cell function (HIV).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Helen Abbott and Dr Keith Chidwick of Technomark Consulting Services Limited
spacer
Dr Helen Abbott
spacer
spacer
spacer
Dr Keith Chidwick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers
 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement